



Supplementary Figure 6. PCA decomposition analysis of CyTOF data from randomized parts arm A and B (**A**), subjects treated with nivo+cabo with or without prior immunotherapy (**B**) and subjects treated with nivo+cabo with or without carcinosarcoma (**C**).